口腔医学 ›› 2023, Vol. 43 ›› Issue (9): 775-780.doi: 10.13591/j.cnki.kqyx.2023.09.002

• 基础研究 • 上一篇    下一篇

二甲双胍调节高糖环境下人牙周膜细胞NLRP3炎症小体激活的机制研究

胡萍1,2,李雯1,饶小波3()   

  1. 1 华中科技大学同济医学院附属同济医院口腔医学中心,湖北武汉(430030)
    2 华中科技大学同济医学院口腔医学院,湖北武汉(430030)
    3 南京大学医学院附属口腔医院,南京市口腔医院第一门诊部,江苏南京(210000)
  • 修回日期:2023-04-16 出版日期:2023-09-28 发布日期:2023-09-28
  • 通讯作者: 饶小波 E-mail:raoxiaobo888@163.com
  • 基金资助:
    湖北省卫生健康科技项目(WJ2021M122)

Metformin regulates NLRP3 inflammasome activation in human periodontal ligament cells under high glucose circumstance

HU Ping1,2,LI Wen1,RAO Xiaobo3()   

  1. Center of Stomatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
  • Revised:2023-04-16 Online:2023-09-28 Published:2023-09-28

摘要:

目的 本研究拟通过体外构建伴糖尿病牙周炎模型,探索二甲双胍对人牙周膜细胞(periodontal ligament cells,PDLCs)中NOD样受体蛋白3(NOD-like receptor protein 3,NLRP3)炎症小体活化的调节能力及其机制,为二甲双胍治疗伴糖尿病牙周炎患者提供新的见解。方法 甲基噻唑基四氮唑比色法检测二甲双胍对人PDLCs的细胞毒性。将人PDLCs细胞分为5组,A组为正常葡萄糖浓度组(8 mmol/L葡萄糖),B组为高渗环境组(8 mmol/L葡萄糖+17 mmol/L的甘露醇),C组为高浓度葡萄糖组(25 mmol/L葡萄糖),D组为高糖环境下二甲双胍处理组(25 mmol/L葡萄糖+40 mmol/L 二甲双胍),E组为高糖环境下二甲双胍和AMPK抑制剂处理组(25 mmol/L葡萄糖+40 mmol/L二甲双胍+10 μmol/L复合物C)。A~E组均暴露在牙龈卟啉单胞菌LPS下,酶联免疫吸附试验检测促炎细胞因子白细胞介素(interleukin, IL)-1β和IL-18表达水平,免疫印迹观察蛋白NLRP3、Caspase-1、ASC、AMPK、p-AMPK表达水平,同时检测线粒体复合体Ⅰ活性变化。结果 二甲双胍浓度不高于40 mmol/L时,对人PDLCs无明显细胞毒性;二甲双胍治疗可显著抑制高糖环境下细胞炎症反应,人PDLCs IL-1β和IL-18分泌减少,NLRP3、Caspase-1表达降低,同时线粒体复合体Ⅰ活性下降,p-AMPK表达升高,引入AMPK抑制剂后可部分逆转上述变化。结论 在人PDLCs中,二甲双胍通过降低线粒体复合体Ⅰ活性和激活AMPKs途径减少高糖环境中NLRP3炎症小体的激活,这为二甲双胍防治伴糖尿病牙周炎提供了新的证据。

关键词: 牙周膜细胞, NOD样受体蛋白3炎症小体, 二甲双胍, 线粒体复合体Ⅰ

Abstract:

Objective To investigate the regulatory ability and mechanism of metformin on the activation of NOD-like receptor protein 3 (NLRP3) in human periodontal ligament cells (PDLCs) by constructing a model of diabetes and periodontitis in vitro, and to provide new insights for metformin in the treatment of patients with diabetes and periodontitis. Methods Methyl thiazolyl tetrazolium assay was used to detect the cytotoxicity of metformin on human PDLCs. Human PDLCs were divided into five groups. Group A was a normal glucose concentration group (8 mmol/L glucose). Group B was a hypertonic environment group (8 mmol/L glucose and 17 mmol/L mannitol). Group C was a high concentration glucose group (25 mmol/L glucose). Group D was a high glucose environment group treated with metformin (25 mmol/L glucose+40 mmol/L metformin). Group E was a high glucose environment group treated with metformin and the AMPK inhibitor (25 mmol/L glucose+40 mmol/L metformin+ 10 μmmol/L compound C). All A-E groups were exposed to Porphyromonas gingivalis LPS at the same time. The level of IL-1β and IL-18 were detected by ELISA. The changes of proteins NLRP3, Caspase-1, ASC, AMPK, and p-AMPK were detected by western blot. Changes of mitochondrial complex Ⅰ activity were also detected. Results Metformin with a concentration not exceeding 40 mmol/L had no significant cytotoxicity on human PDLCs. Metformin treatment could significantly inhibit the inflammatory response in high glucose environments, characterized by the decrease of IL-1β, IL-18, NLRP3 and Caspase-1, and also reducing the activity of mitochondrial complex Ⅰ, while increasing the expression of p-AMPK. However, the introduction of AMPK inhibitor reversed some of the changes. Conclusion In human PDLCs, metformin reduces the activation of NLRP3 inflammasome in high glucose environment by reducing the activity of mitochondrial complex Ⅰ and activating AMPKs pathway, which provides new evidence for metformin to prevent and treat diabetes patients with periodontitis.

Key words: periodontal ligament cells, NOD-like receptor protein 3 inflammasome, metformin, mitochondrial complex Ⅰ

中图分类号: